Table 12 Neromuscular effects of mivacurium in paediatric patients in group D (mean ± SD, S)
From: The efficacy and safety of mivacurium in pediatric patients
Subgroups | n | Onset time | T1 5% recovery | T1 25% recovery | Recovery index | TOF ratio 90% |
|---|---|---|---|---|---|---|
Group 13 | 40 | 184 ± 57 | 376 ± 116 | 796 ± 207 | 299 ± 80 | 911 ± 214 |
Group 14 | 40 | 187 ± 66 | 389 ± 116 | 796 ± 199 | 304 ± 94 | 998 ± 239 |
Group 15 | 40 | 181 ± 58 | 369 ± 95 | 789 ± 193 | 289 ± 79 | 974 ± 251 |
Group 16 | 40 | 182 ± 56 | 363 ± 116 | 794 ± 196 | 296 ± 95 | 963 ± 252 |